Do you want to read an article? Please log in or register.
Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation
Lung Cancer
Related content
RECOMMENDED
Lung Cancer
A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Zerdes I, Kamali C, Johannsdottir B, Blasi M, Assmann C, Kazdal D, Stenzinger A, Skribek M, Ekman S, Christopoulos P, Tsakonas G
doi: 10.1016/j.lungcan.2024.108065
Lung Cancer
Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
Clin Lung Cancer
Masuda T, Katsumata S, Isaka M, Serizawa M, Kawata T, Asami M, Yamaguchi D, Matsushima K, Hayasaka K, Kojima H, Yokomakura N, Konno H, Nagashima T, Urakami K, Yamaguchi K, Ohde Y
doi: 10.1016/j.cllc.2025.04.009
Lung Cancer
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer
Clin Lung Cancer
Sun F, Nagpal S, Singhal S, Neal JW, Wakelee HA, Myall NJ, Bolan P, Riess JW, Gandara DR, Das MS
doi: 10.1016/j.cllc.2025.08.002
Lung Cancer
In the context of the era of targeted therapy: evaluation of the survival benefits of different local treatment modalities for patients with 1-3 brain metastases from non-small cell lung cancer
Sci Rep
Sun L, Chen H, Yang Z, Li L, Ying Z, Qu Y, Tong N, Sun C, Xia L
doi: 10.1038/s41598-025-10042-w
Lung Cancer
Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis
Clin Lung Cancer
Zeng Z, Feng S, Gao T, Chen C, Chen J, Chen J, Lian Y
doi: 10.1016/j.cllc.2025.04.010
RECOMMENDED
Lung Cancer
Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung Adenocarcinoma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Tajè R, Ambrogi V, Tacconi F, Gallina FT, Alessandrini G, Forcella D, Buglioni S, Visca P, Patirelis A, Cecere FL, Melis E, Vidiri A, Sperduti I, Cappuzzo F, Novello S, Caterino M, Facciolo F
doi: 10.1016/j.cllc.2025.01.001
RECOMMENDED
Lung Cancer
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla M, Occhipinti M, Mazzeo L, Beninato T, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, Russo GL, Prelaj A
doi: 10.1016/j.lungcan.2024.108051
Lung Cancer
KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort
J Clin Med
Geçgel A, Şahin Çelik B, Peker P, Gökdere ZS, Koca D, Karaca B, Nart D, Göker E
doi: 10.3390/jcm14196826
Lung Cancer
High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models
Nat Commun
Álvarez-Pérez JC, Sanjuán-Hidalgo J, Arenas AM, Hernández-Navas I, Benitez-Cantos MS, Andrades A, Calabuig-Fariñas S, Jantus-Lewintre E, Paz-Ares L, Ferrer I, Medina PP
doi: 10.1038/s41467-025-62350-4